ERBB2 and breast cancer: By using Panobinostat, Belinostat, Vorinostat and Valproic acid dose-dependently to measure breast cancer cell viability for 48 h, we found Panobinostat and Belinostat significantly inhibited cell growth on MDA-MB-231 cells (TNBC, Figure 2A), rather than SK-BR-3 (HER2-enriched, Figure 2B) and MCF-7 (luminal, Figure 2C) cells.